0000000000261605

AUTHOR

Monica Terenziani

showing 8 related works from this author

Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experienc…

2020

Background Malignant germ cell tumors (GCTs) are a heterogeneous group of rare neoplasms in children. Optimal outcome is achieved with multimodal therapies for patients with both localized and advanced disease, especially after the introduction of platinum-based chemotherapy regimens. In this respect, data on salvage treatment for children with relapsed or platinum-refractory disease are still limited. Methods Retrospective analysis of data regarding patients affected by malignant GCTs with platinum-refractory or relapsed disease after first-line treatment according to AIEOP TCGM 2004 protocol was conducted. Results Twenty-one patients, 15 females and 6 males, were considered for the analys…

OncologyMelphalanMalemedicine.medical_treatmentDrug ResistanceSalvage therapyrelapsed tumorsDeoxycytidineCarboplatinchemistry.chemical_compound0302 clinical medicineNeoplasmsAntineoplastic Combined Chemotherapy Protocolsgerm cell tumorsChildEtoposideIfosfamideRemission InductionHematologyNeoplasms Germ Cell and EmbryonalPrognosisgerm cell tumors; high-dose chemotherapy; pediatric tumors; refractory tumors; relapsed tumors; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child Preschool; Cisplatin; Deoxycytidine; Drug Resistance Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence Local; Neoplasms Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Salvage Therapypediatric tumorsOxaliplatinSurvival RateLocalOncology030220 oncology & carcinogenesisChild PreschoolFemalerefractory tumorsmedicine.drugmedicine.medical_specialtyAdolescentPaclitaxelThioTEPA03 medical and health sciencesInternal medicinemedicineHumansIfosfamidePreschoolSurvival rateRetrospective StudiesSalvage TherapyChemotherapybusiness.industryInfantmedicine.diseaseGemcitabineCarboplatinNeoplasm RecurrencechemistryDrug Resistance NeoplasmPediatrics Perinatology and Child HealthSettore MED/20NeoplasmGerm Cell and EmbryonalGerm cell tumorsCisplatinNeoplasm Recurrence Localbusinesshigh-dose chemotherapy030215 immunologyFollow-Up StudiesPediatric bloodcancerREFERENCES
researchProduct

Malignant ovarian germ cell tumors in pediatric patients: The AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) study.

2017

Objective Malignant ovarian germ cell tumors (MOGCT) carry an excellent prognosis, and the treatment aims to achieve results with the least possible treatment-related morbidity. The aim of this study was to assess the outcomes of pediatric patients with MOGCT. Methods Patients were treated according to their stage: surgery and surveillance for stage I; a modified bleomycin–etoposide–cisplatin (BEP) regimen for stages II (three cycles), III, and IV (three cycles) with surgery on residual disease. Results Seventy-seven patients were enrolled (median age 11.8 years), 26 with dysgerminoma (Dysg), 13 with immature teratoma and elevated serum alpha-fetoprotein levels (IT + AFP), and 38 with nondy…

0301 basic medicineMalechildhood; germ cell tumors; ovarianGastroenterology0302 clinical medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineProspective StudiesStage (cooking)germ cell tumorsProspective cohort studyChildEtoposideOvarian NeoplasmsHematologychildhood germ cell tumors ovarianNeoplasms Germ Cell and EmbryonalPrognosisCombined Modality TherapySurvival RateOncology030220 oncology & carcinogenesisChild PreschoolFemalemedicine.medical_specialtyAdolescentOvariectomy03 medical and health sciencesBleomycinInternal medicineDysgerminomaovarianHumansSurvival ratechildhoodNeoplasm Stagingbusiness.industrySettore MED/20 - Chirurgia Pediatrica E InfantileInfantmedicine.diseaseSurgeryRegimen030104 developmental biologyPediatrics Perinatology and Child HealthSettore MED/20Immature teratomaGerm cell tumorsCisplatinbusinessProgressive diseaseFollow-Up StudiesPediatric bloodcancer
researchProduct

Bax mutation and overexpression inversely correlate with immature phenotype and prognosis of childhood germ cell tumors

2007

Primary childhood germ cell tumors (GCTs) represent a rare and heterogeneous group of tumors that varies in histologic differentiation, age of presentation and clinical outcome. In malignant neoplasms, apoptosis is a prognostic marker and a predictive factor of response to therapy. Therefore, the study of the expression and mutation of molecules involved in the regulation of apoptosis could be useful in order to both predict the clinical outcome and design self-tailored therapeutic approaches. We retrospectively analysed tissue samples of 54 childhood GCTs. The expression of p53 and BAX protein was assessed by immunohistochemistry (IHC). Moreover, we investigated the presence of mutations i…

MaleCancer ResearchPathologymedicine.medical_specialtyAdolescentBcl-2-associated X proteinmedicineHumansChildRetrospective Studiesbcl-2-Associated X ProteinOncogenebiologyImmunochemistryInfant NewbornCancerInfantGeneral MedicineCell cycleNeoplasms Germ Cell and Embryonalmedicine.diseaseGenes p53PrognosisMolecular medicinePhenotypeOncologyChild PreschoolMutationbiology.proteinImmunohistochemistryImmature teratomaFemaleGerm cell tumorsTumor Suppressor Protein p53
researchProduct

Teratoma with a malignant somatic component in pediatric patients: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experience

2010

Background Teratoma with a malignant somatic component (TMSC) is rare but described in adults, whereas information on pediatric presentation is sparse. Procedure The Associazione Italiana Ematologia Oncologia Pediatrica identified 14 cases of TMSC. Clinical files and pathology specimens were reviewed. Results The series (9 female, 5 male) showed the following disease: testis (2), sacrococcygeal (3), ovary (3), retroperitoneum (3), mediastinum (2), and foot soft tissue (1). Distribution of the somatic component was: carcinoma (4), pancreatic neuroendocrine tumor (1), neuroblastoma (3), rhabdomyosarcoma (3), rhabdomyosarcoma plus liposarcoma, chondrosarcoma, neurogenic sarcoma (1), chondrosar…

medicine.medical_specialtyPathologybusiness.industryMalignant peripheral nerve sheath tumorHematologyLiposarcomamedicine.diseaseOncologyPediatrics Perinatology and Child HealthmedicineCarcinomaRadiologyGerm cell tumorsTeratomaSarcomaChondrosarcomaRhabdomyosarcomabusinessPediatric Blood & Cancer
researchProduct

Impact of era of diagnosis on cause-specific late mortality among 77 423 five-year European survivors of childhood and adolescent cancer:The PanCareS…

2022

Late mortality of European five-year survivors of childhood or adolescent cancer has dropped over the last 60 years, but excess mortality persists. There is little information concerning secular trends in cause-specific mortality among older European survivors. PanCareSurFup pooled data from 12 cancer registries and clinics in 11 European countries from 77 423 five-year survivors of cancer diagnosed before age 21 between 1940 to 2008 followed for an average age of 21 years and a total of 1.27 million person-years to determine their risk of death using cumulative mortality, standardized mortality ratios (SMR), absolute excess risks (AER), and multivariable proportional hazards regression ana…

AdultMaleCancer ResearchSecond NeoplasmsAdolescentAdolescent cancercauses of deathEuropean03 medical and health sciencesYoung Adult0302 clinical medicineCancer SurvivorsCause of DeathMedicineHumans030212 general & internal medicineCause specificChild610 Medicine & healthAgedExcess mortalitybusiness.industrycardiovascularsecond malignant neoplasmsHazard ratioCancersurvivors of childhood cancerMiddle Agedmedicine.diseaseConfidence interval3. Good healthOncologyEuropean; cardiovascular; causes of death; late mortality; second malignant neoplasms; survivors of childhood cancer030220 oncology & carcinogenesisChild Preschoollate mortalityFemaleRisk of deathbusiness360 Social problems & social servicesDemography
researchProduct

Get up, stand up: Alongside adolescents and young adults with cancer for their right to be forgotten

2022

Adolescent and young adult cancer survivors may experience various forms of social difficulties years or even decades after completing their cancer treatments. This article will hopefully help the Italian national project dedicated to adolescents and young adults with cancer promoting political and legal solutions to stop discrimination and supporting the right to be forgotten.

young adultsCancer ResearchAdolescentAYAsurvivorsGeneral MedicineAdolescentsCancer SurvivorsOncologyItalyNeoplasmsSettore M-PSI/08 - Psicologia ClinicasurvivorHumansyoung adultright to be forgottenAYA; Adolescents; Italy; right to be forgotten; survivors; young adults
researchProduct

Risk of digestive cancers in a cohort of 69 460 five-year survivors of childhood cancer in Europe: the PanCareSurFup study.

2021

BackgroundSurvivors of childhood cancer are at risk of subsequent primary neoplasms (SPNs), but the risk of developing specific digestive SPNs beyond age 40 years remains uncertain. We investigated risks of specific digestive SPNs within the largest available cohort worldwide.MethodsThe PanCareSurFup cohort includes 69 460 five-year survivors of childhood cancer from 12 countries in Europe. Risks of digestive SPNs were quantified using standardised incidence ratios (SIRs), absolute excess risks and cumulative incidence.Results427 digestive SPNs (214 colorectal, 62 liver, 48 stomach, 44 pancreas, 59 other) were diagnosed in 413 survivors. Wilms tumour (WT) and Hodgkin lymphoma (HL) survivors…

medicine.medical_specialtyColorectal cancerPopulation03 medical and health sciences0302 clinical medicineInternal medicineEpidemiology of cancerCOLORECTAL CANCER SCREENINGmedicineCumulative incidence030212 general & internal medicineGastrointestinal cancerFamily historyeducation610 Medicine & healthGASTROINTESTINAL CANCERCOLORECTAL CANCEReducation.field_of_studybusiness.industryIncidence (epidemiology)Gastroenterologymedicine.disease030220 oncology & carcinogenesisCohortCANCER EPIDEMIOLOGYbusiness360 Social problems & social servicesGut
researchProduct

Abdomen/pelvis computed tomography in staging of pediatric Hodgkin Lymphoma: is it always necessary?

2016

Abstract The purpose of the study was to determine if abdomen/pelvis computed tomography (CT) can be safety omitted in the initial staging of a subgroup of children affected by Hodgkin Lymphoma (HL). Every participating center of A.I.E.O.P (Associazione Italiana di Ematologia ed Oncologia Pediatrica) sent local staging reports of 18F‐fluorodeoxyglucose positron emission tomography (PET) and abdominal ultrasound (US) along with digital images of staging abdomen/pelvis CT to the investigation center where the CT scans were evaluated by an experienced pediatric radiologist. The local radiologist who performed the US was unaware of local CT and PET reports (both carried out after US), and the r…

MaleCancer Researchmedicine.medical_specialtyPediatric RadiologistComputed tomographyMultimodal ImagingSensitivity and SpecificityPelvis03 medical and health sciences0302 clinical medicinePositron Emission Tomography Computed TomographyAbdomenmedicineHumansRadiology Nuclear Medicine and imagingIn patient030212 general & internal medicinePelvisNeoplasm StagingOriginal Researchmedicine.diagnostic_testHodgkin Lymphomabusiness.industryAbdomen+PelvisClinical Cancer ResearchHodgkin DiseaseChildhoodPETmedicine.anatomical_structureOncologyPositron emission tomographyPositron-Emission Tomography030220 oncology & carcinogenesisHodgkin lymphomaAbdomenFemaleLymph NodesRadiologyTomography X-Ray ComputedbusinessCancer Medicine
researchProduct